Pfizer is to acquire commercial-stage biopharmaceutical company Biohaven in a deal worth $11.6 billion. Biohaven is developing therapies for the treatment of migraine. The company’s lead product NURTEC ODT is a dual-acting migraine therapy which has been approved in the US for adult patients. The therapy has also been approved in the EU for both […]
